A Phase I, Single Center, Open Label, Randomized, Single-Dose, Three-Way Crossover Study to Compare the Pharmacokinetics and Bioavailability of Two NP101 (Sumatriptan Iontophoretic Transdermal Patch) With an Oral Formulation of Imitrex in Healthy Volunteers and to Collect Resistance Data During Application of NP101.
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2012
At a glance
- Drugs Sumatriptan (Primary) ; Sumatriptan (Primary)
- Indications Migraine
- Focus Pharmacokinetics
- 08 Nov 2012 Primary endpoints amended as reported by ClinicalTrials.gov.
- 29 Jun 2011 New trial record